Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Bristol Myers Squibb Company BMY

Healthcare  —  Drug Manufacturers General
62.86 1.36 2.21% as of 25 Sep
Market cap
$125.9B
P/E
13.8×
S&P 500 Member Dividend Aristocrat
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Bristol Myers Squibb Company (BMY) Price to free cash flow

As of 25 September 2026, Bristol Myers Squibb Company (BMY) trades at a price to free cash flow of 11.2×. Over the past ten years it has ranged from 5.7× (October 2025) to 382× (June 2016); the current reading is higher than 42% of that period. That is below the Drug Manufacturers General industry median of 17.7× and below the Healthcare sector median of 19.5×.

Price to free cash flow, daily

Annual

Period Price to free cash flow Change
FY2025 8.5× 3.87%
FY2024 8.2× (4.70%)
FY2023 8.6× (33.02%)
FY2022 12.9× 41.71%
FY2021 9.1× (13.69%)
FY2020 10.5× (29.04%)
FY2019 14.8× 6.92%
FY2018 13.9× (41.92%)
FY2017 23.9× (55.66%)
FY2016 53.9× (39.60%)

Quarterly

Period Price to free cash flow Change
Jun 2026 10.3× (0.92%)
Mar 2026 10.4× 21.53%
Dec 2025 8.5× 42.34%
Sep 2025 6.0× (7.13%)
42 more quarters

Against its own ten years

Low 5.7× High 382×
Ten-year median 12.0×
Current reading's percentile 42

Price to free cash flow against peers

Company Price to free cash flow
SNY Sanofi compare 6.8×
BMY Bristol Myers Squibb Company 11.2×
GSK GSK PLC Sponsored ADR compare 12.9×
GILD Gilead Sciences, Inc. compare 14.5×
PFE Pfizer Inc. compare 16.0×
NVS Novartis AG compare 18.3×
NVO Novo Nordisk A/S compare 22.6×
AMGN Amgen Inc. compare 23.0×
AZN AstraZeneca PLC compare 41.2×
Drug Manufacturers General industry median 17.7×
Healthcare sector median 19.5×
Market median 14.0×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on BMY